- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04164446
Supplementation of Oil Palm Phenolics to Healthy Participants (SPIRAL)
Supplementation of Oil Palm Phenolics to Improve Lipid Profile in Healthy Participants (Phase I Clinical Trial Study)
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
During the palm oil milling process, a large amount of vegetation liquor is discarded into the aqueous waste stream. A novel process to recover phenolic compounds from the aqueous waste stream were developed and resulting in producing a filtrate known as oil palm phenolics (OPP), which contains a high amount of phenolic. It has been postulated that phenolic acids components found in the OPP have promising health benefits such as antioxidant, anti-inflammatory, neuroprotective and anti-tumour effects.
Hyperlipidemia, one of the risk factors for cardiovascular diseases (CVD), is defined as elevations of fasting total cholesterol or triglyceride concentration or both. Through our current research, OPP supplementation to hamster animal model has shown positive effects in the reduction of total cholesterol and triglycerides as well as improvement of high-density lipoprotein cholesterol (HDL-C). In a previous study using the rabbit animal model, OPP has shown a protective effect against atherosclerosis, a condition whereby fat and cholesterol plaques are deposited inside the arteries. Based on the current evidence from the preliminary studies on OPP, we hypothesize that supplementation of OPP may prevent or delay the development of CVD.
However, to understand the anti-hyperlipidemic effects of OPP in humans, we need to establish our knowledge of the physiological effects of this compound to normal human subjects. Under physiological condition, OPP may improve the antioxidant and anti-inflammatory status. These improvements may have a positive influence on plasma lipid profile since many scientific evidences demonstrate that antioxidant and anti-inflammatory effects may contribute protection against the incidence of CVD. Therefore, we proposed a clinical trial to evaluate the antioxidant and anti-inflammatory effects of OPP in eliciting the possible mechanism for lipid reduction.
This study will be started with the recruitment of 100 healthy volunteers where they will be supplemented with placebo/OPP capsules at different doses for 60 days. Participants will be required to take the placebo/OPP capsules in front of the study staff to ensure compliance. Blood samples will be withdrawn at baseline, day 30 and day 60, and will be analyzed for lipid profile, antioxidant and anti-inflammatory status. Data from this study would hopefully assist us in understanding the therapeutic roles of OPP on humans under normal conditions.
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
- Name: Nurul Izzah Ibrahim, PhD
- Telefonnummer: +60132678770
- E-Mail: nurulizzah88@gmail.com
Studieren Sie die Kontaktsicherung
- Name: Isa Naina Mohamed, MD, PhD
- Telefonnummer: +60391459568
- E-Mail: isanaina@ppukm.edu.my
Studienorte
-
-
WP Kuala Lumpur
-
Cheras, WP Kuala Lumpur, Malaysia, 56000
- Rekrutierung
- National University of Malaysia
-
Kontakt:
- Nurul Izzah Ibrahim, PhD
- Telefonnummer: +60132678770
- E-Mail: nurulizzah88@gmail.com
-
Hauptermittler:
- Isa Naina Mohamed, MD, PhD
-
Unterermittler:
- Qodriah Mohd Saad, MBBS, PhD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Healthy
- Normal Total Cholesterol level of less than 5.2 mmol/dL
- Normal LDL Cholesterol level of less than 3.36 mmol/dL
- Normal Triglyceride level of less than 1.69 mmol/dL
Exclusion Criteria:
- Smoking
- Habitual alcohol consumption
- Consuming antioxidant supplement
- Pregnant/ breastfeeding
- Medical history of cardiovascular disease, diabetes, dyslipidemia
- Current use of antihypertensive or lipid-lowering medication
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Placebo-Komparator: Placebo
Two capsules containing starch and glucose, once per day, 60 days duration
|
The placebo that will be used contains starch and glucose.
Andere Namen:
|
Aktiver Komparator: Oil Palm Phenolics 250 mg
One capsule 250 mg active compound (OPP) and one capsule containing starch and glucose, once per day, 60 days duration
|
One capsule contains 250 mg OPP or 1 g OPP
|
Aktiver Komparator: Oil Palm Phenolics 1000 mg
One capsule containing 1000 mg active compound (OPP) and one capsule starch and glucose, once per day, 60 days duration
|
One capsule contains 250 mg OPP or 1 g OPP
|
Aktiver Komparator: Oil Palm Phenolics 2000 mg
Two capsules, 1000 mg active compound (OPP) each, once per day, 60 days duration
|
One capsule contains 250 mg OPP or 1 g OPP
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Changes from Baseline Fasting Plasma LDL Cholesterol level following one and two months supplementation
Zeitfenster: Baseline, day 30, day 60
|
This will be assessed from the plasma analysis on the fasting blood samples of each participant
|
Baseline, day 30, day 60
|
Incidence of Adverse Events following one-month supplementation (Safety and Tolerability)
Zeitfenster: Day 30 after supplementation
|
This will be assessed via history, physical examination, kidney function test, liver function test and hematology profile from the plasma analysis on the fasting blood samples of each participant.
|
Day 30 after supplementation
|
Incidence of Adverse Events following two-months supplementation (Safety and Tolerability)
Zeitfenster: Day 60 after supplementation
|
This will be assessed via history, physical examination, kidney function test, liver function test and hematology profile from the plasma analysis on the fasting blood samples of each participant.
|
Day 60 after supplementation
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Changes from Baseline Fasting Lipid Profile (total and HDL cholesterol, triacylglycerides) following one and two months supplementation
Zeitfenster: Baseline, day 30 and day 60 after supplementation
|
This will be assessed from the plasma analysis on the fasting blood samples of each participant.
|
Baseline, day 30 and day 60 after supplementation
|
Changes from Baseline Fasting LDL and HDL Cholesterol Subfractions following one and two months supplementation.
Zeitfenster: Baseline, day 30 and day 60 after supplementation
|
This will be assessed from the plasma analysis on the fasting blood samples of each participant.
|
Baseline, day 30 and day 60 after supplementation
|
Changes from Baseline Concentrations of Plasma Inflammatory Markers using multiplex assays following one and two months supplementation
Zeitfenster: Baseline,day 30 and day 60 after supplementation
|
Inflammatory markers such as Interleukin-6, Interleukin-1beta, Tumour Necrosis Factor-alpha, Interleukin-10 and interferon-Gamma will be assessed from the plasma analysis on the fasting blood samples of each participant.
|
Baseline,day 30 and day 60 after supplementation
|
Changes from Baseline Concentrations of Plasma Antioxidant Levels using ELISA method following one and two months supplementation
Zeitfenster: Baseline,day 30 and day 60 after supplementation
|
Antioxidant levels such as Malonaldehyde and Superoxide dismutase will be assessed from the plasma analysis on the fasting blood samples of each participant.
|
Baseline,day 30 and day 60 after supplementation
|
Changes from Baseline Body Weight Measurement following one and two months supplementation
Zeitfenster: Baseline,day 30 and day 60 after supplementation
|
This will be assessed by measuring the weight of each participant.
|
Baseline,day 30 and day 60 after supplementation
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Isa Naina Mohamed, MD, PhD, National University of Malaysia
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Fairus S, Leow SS, Mohamed IN, Tan YA, Sundram K, Sambanthamurthi R. A phase I single-blind clinical trial to evaluate the safety of oil palm phenolics (OPP) supplementation in healthy volunteers. Sci Rep. 2018 May 29;8(1):8217. doi: 10.1038/s41598-018-26384-7.
- Muhammad Ismail Tadj NB, Ibrahim N', Haji Mohd Saad Q, Tg Abu Bakar Sidik TMI, Leow SS, Fairus S, Naina Mohamed I. A Phase I, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Tolerance of Oil Palm Phenolics (OPP) in Healthy Volunteers. Front Pharmacol. 2022 Jun 20;13:893171. doi: 10.3389/fphar.2022.893171. eCollection 2022.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- SPIRAL
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Placebos
-
Yiling Pharmaceutical Inc.Abgeschlossen
-
Nova Scotia Health AuthorityRekrutierung
-
Laval UniversityLallemand Health SolutionsAbgeschlossen
-
Università Vita-Salute San RaffaeleAktiv, nicht rekrutierendHerzchirugieItalien, Singapur, Kroatien
-
Intra-Cellular Therapies, Inc.AbgeschlossenBipolare Depression | DepressionVereinigte Staaten, Bulgarien, Russische Föderation, Serbien, Ukraine
-
Josef Smolen, Univ. Prof. Dr.Unbekannt
-
GE HealthcareSyneos HealthBeendetChronische NierenerkrankungenVereinigte Staaten, Spanien, Belgien, Kanada, Polen, Vereinigtes Königreich
-
Viela BioCTI Clinical Trial and Consulting ServicesBeendet
-
Nanjing Sanhome Pharmaceutical, Co., Ltd.Abgeschlossen
-
Viking Therapeutics, Inc.Aktiv, nicht rekrutierendNASH – Nichtalkoholische SteatohepatitisVereinigte Staaten, Belgien, Frankreich, Mexiko, Puerto Rico